This Project has been agreed as part of the Accelerated Access Collaborative (AAC). The AAC was formed in response to the independently-chaired Accelerated Access Review published in October 2016. The AAC brings industry, government and the NHS together to remove barriers to uptake of innovations, so that NHS patients have faster access to certain products that can transform care.
The AAC supports the rapid uptake of products from 7 high-potential technology areas, selected by leaders in the health and care system, with full evidence-based recommendations from NICE.
PCSK9 inhibitors for the management of hypercholesterolemia were selected as one of the seven NICE recommended rapid uptake products to increase patient access and remove barriers across the health innovation landscape.
Funding announced by government in July 2017 is available through the new Accelerated Access Collaborative Pathway Transformation Fund (PTF) to help NHS organisations integrate the rapid uptake products into everyday practice. Delivered with the support of the Academic Health Science Networks (AHSNs) the PTF seeks to improve equality of access to these products.
The PTF, in relation to PCSK9 inhibitors, combines funding from NHS England, Amgen and Sanofi for selected projects to meet the AAC objectives and increase PCSK9i uptake by addressing barriers such as:
- Lack of patient identification
- Inconsistent pathways
- Limited awareness
- Restricted prescribing
- Sporadic LDL-C measurement
- Treatment complexity
19 applications relating to PCSK9 inhibitors from 12 AHSNs were submitted to the AAC for funding from NHS England, Amgen and Sanofi and 6 were selected, including University Hospitals of Leicester NHS Trust.
NHS England have provided Pathway Transformation Funding to the Academic Health and Science Network North East North Cumbria (AHSN-NENC). AHSN-NENC will distribute this accordingly as agreed by the AAC to the 6 successful sites, one of which being the Partner for this project.
The overall aim of University Hospitals of Leicester NHS Trust working in partnership with primary care and Amgen / Sanofi is to improve the identification and management of patients with familial hypercholesterolaemia (FH) and patients with cardiovascular disease and primary hypercholesterolaemia / mixed dyslipidaemia. Improved cholesterol management will reduce the cardiovascular disease risk for these patients.
UHL will seek to employ a clinical pharmacist or nurse with admin support to work on the project and achieve the following objectives:
- Undertake a systematic search of GP records to identify patients with potential FH and patients with cardiovascular disease and primary hypercholesterolaemia / mixed dyslipidaemia.
- Clinical pharmacist / nurse led review of high-risk patients in primary care to optimise cholesterol management.
- Identification of patients with elevated LDL-C despite maximal lipid lowering medications and referral of these patients to the lipid clinic to review treatment options to improve LDL-C.